CYP2C19 and ischemic stroke: In our study the ADP induced platelet aggregation (U) level for CYP2C19*2, CYP2C19*3 polymorphism for variant allele was found to be higher compared to the wild type allele in responders, non-responders group of clopidogrel treated ischemic stroke patients and concluded that CYP2C19*2 or *3 LOF alleles were independently associated to ADP-PA measurement.23 Hulot and colleagues24 showed that the CYP2C19 loss-of-function allele is associated with a marked decrease in platelet responsiveness to clopidogrel in 28 young healthy male subjects treated for 7 days with clopidogrel 75 mg/day.